NSAIDs for early management of acute respiratory infections.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
24 May 2024
24 May 2024
Historique:
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
To review the rationale for and the potential clinical benefits of an early approach to viral acute respiratory infections with NSAIDs to switch off the inflammatory cascade before the inflammatory process becomes complicated. It has been shown that in COVID-19 as in other viral respiratory infections proinflammatory cytokines are produced, which are responsible of respiratory and systemic symptoms. There have been concerns that NSAIDs could increase susceptibility to SARS-CoV-2 infection or aggravate COVID-19. However, recent articles reviewing experimental research, observational clinical studies, randomized clinical trials, and meta-analyses conclude that there is no basis to limit the use of NSAIDs, which may instead represent effective self-care measures to control symptoms. The inflammatory response plays a pivotal role in the early phase of acute respiratory tract infections (ARTIs); a correct diagnosis of the cause and a prompt therapeutic approach with NSAIDs may have the potential to control the pathophysiological mechanisms that can complicate the condition, while reducing symptoms to the benefit of the patient. A timely treatment with NSAIDs may limit the inappropriate use of other categories of drugs, such as antibiotics, which are useless when viral cause is confirmed and whose inappropriate use is responsible for the development of resistance.
Identifiants
pubmed: 38779903
doi: 10.1097/QCO.0000000000001024
pii: 00001432-990000000-00148
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Shahan B, Barstow C, Mahowald M. Respiratory conditions: upper respiratory tract infections. FP Essent 2019; 486:11–18.
Santus P, Radovanovic D, Gismondo MR, et al. Respiratory syncytial virus burden and risk factors for severe disease in patients presenting to the emergency department with flu-like symptoms or acute respiratory failure. Respir Med 2023; 218:107404.
Kuchar E, Miśkiewicz K, Nitsch-Osuch A, Szenborn L. Pathophysiology of clinical symptoms in acute viral respiratory tract infections. Adv Exp Med Biol 2015; 857:25–38.
Marseglia GL, Veraldi D, Ciprandi G. Study Group on Respiratory Infections in Adolescents Ketoprofen lysine salt treatment in adolescents with acute upper respiratory infections: a primary-care experience. Minerva Pediatr (Torino) 2023; 75:890–895.
Forchette L, Sebastian W, Liu T. A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci 2021; 41:1037–1051.
Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 2020; 9:761–770.
Pedersen SG, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020; 130:2202–2205.
Pinto R, Herold S, Cakarova L, et al. Inhibition of influenza virus-induced NF-kappaB and raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res 2011; 92:45–56.
Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of nonsteroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem 2012; 11:52–64.
Megha KB, Joseph X, Akhil V, Mohanan PV. Cascade of immune mechanism and consequences of inflammatory disorders. Phytomedicine 2021; 91:153712.
Chamkouri N, Absalan F, Koolivand Z, Yousefi M. Nonsteroidal anti-inflammatory drugs in viral infections disease, specially COVID-19. Adv Biomed Res 2023; 12:20.
Kulesza A, Paczek L, Burdzinska A. The role of COX-2 and PGE2 in the regulation of immunomodulation and other functions of mesenchymal stromal cells. Biomedicines 2023; 11:445.
Asa’ad F, Cho YD, Larson L. Editorial: on the inflammatory cascade-from bacteria through the epithelium to the connective tissue. Front Cell Infect Microbiol 2022; 12:936833.
Robb CT, Goepp M, Rossi AG, Yao C. Nonsteroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol 2020; 177:4899–4920.
Wright WR, Kirkby NS, Galloway-Phillipps NA, et al. Cyclooxygenase and cytokine regulation in lung fibroblasts activated with viral versus bacterial pathogen associated molecular patterns. Prostaglandins Other Lipid Mediat 2013; 107:4–12.
Hussell T, Goulding J. Structured regulation of inflammation during respiratory viral infection. Lancet Infect Dis 2010; 10:360–366.
Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76:16–32.
Liu L, Li R, Pan Y, et al. High-throughput screen of protein expression levels induced by cyclooxygenase-2 during influenza a virus infection. Clin Chim Acta 2011; 412:1081–1085.
Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res 2011; 91:330–334.
Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral activity of a selective COX-2 inhibitor NS-398 on avian influenza H5N1 infection. Influenza Other Respir Viruses 2011; 5: (Suppl 1): 230–232.
Lee S, Cheung CY, Nicholls JM, et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 2008; 198:525–535.
Lee MY, Cheung CY, Peiris JS. Role of cyclooxygenase-2 in H5N1 viral pathogenesis and the potential use of its inhibitors. Hong Kong Med J 2013; 19: (Suppl 4): 29–35.
Lund LC, Reilev M, Hallas J, et al. Association of nonsteroidal anti-inflammatory drug use and adverse outcomes among patients hospitalized with influenza. JAMA Netw Open 2020; 3:e2013880.
Marcianò G, Muraca L, Rania V, Gallelli L. Ibuprofen in the management of viral infections: the lesson of COVID-19 for its use in a clinical setting. J Clin Pharmacol 2023; 63:975–992.
Fazio S, Bellavite P, Zanolin E, et al. Retrospective study of outcomes and hospitalization rates of patients in Italy with a confirmed diagnosis of early COVID-19 and treated at home within 3 days or after 3 days of symptom onset with prescribed and non-prescribed treatments between November 2020 and August 2021. Med Sci Monit 2021; 27:e935379.
Hunt CM, Efird JT, Redding TS 4th, et al. Medications associated with lower mortality in a SARS-CoV-2 positive cohort of 26,508 Veterans. J Gen Intern Med 2022; 37:4144–4152.
Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96:7563–7568.
Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, et al. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome. Anesthesiology 2022; 136:843–860.
Basille D, Plouvier N, Trouve C, et al. Nonsteroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia: a cohort study. Lung 2017; 195:201–208.
Voiriot G, Philippot Q, Elabbadi A, et al. Risks related to the use of nonsteroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med 2019; 8:786.
Stuart B, Venekamp R, Hounkpatin H, et al. NSAID prescribing and adverse outcomes in common infections: a population-based cohort study. BMJ Open 2024; 14:e077365.
Micallef J, Soeiro T, Jonville-Béra A. French Society of Pharmacology, Therapeutics (SFPT) Nonsteroidal antiinflammatory drugs, pharmacology, and COVID-19 infection. Therapie 2020; 75:355–362.
Sodhi M, Khosrow-Khavar F, FitzGerald JM, Etminan M. Nonsteroidal anti-inflammatory drugs and the risk of pneumonia complications: a systematic review. Pharmacotherapy 2020; 40:970–977.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China. JAMA Intern Med 2020; 180:934.
Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of nonsteroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17:e1003308.
von Philipsborn P, Biallas R, Burns J, et al. Adverse effects of nonsteroidal anti-inflammatory drugs in patients with viral respiratory infections: rapid systematic review. BMJ Open 2020; 10:e040990.
Laughey W, Lodhi I, Pennick G, et al. Ibuprofen, other NSAIDs and COVID-19: a narrative review. Inflammopharmacology 2023; 31:2147–2159.
Prada L, D Santos C, Baião RA, et al. Risk of SARS-CoV-2 infection and COVID-19 severity associated with exposure to nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. J Clin Pharmacol 2021; 61:1521–1533.
Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020; 288:469–476.
Lee MW, Katz PO. Nonsteroidal antiinflammatory drugs, anticoagulation, and upper gastrointestinal bleeding. Clin Geriatr Med 2021; 37:31–42.
Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24:121–132.
Brandolini L, d’Angelo M, Antonosante A, et al. Differential protein modulation by ketoprofen and ibuprofen underlines different cellular response by gastric epithelium. J Cell Physiol 2018; 233:2304–2312.
Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009; 8:669–681.
Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (nonaspirin) NSAIDs. Nat Rev Cardiol 2020; 17:574–584.
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo- oxygenase-2 inhibitors and traditional non steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta- analysis of randomized trials. BMJ 2006; 332:1302–1308.
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of nonsteroidal anti inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.
Masclee GMC, Straatman H, Arfè A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project. PLoS One 2018; 13:e0204746.
Moore N, Bosco-Levy P, Thurin N, et al. NSAIDs and COVID-19: a systematic review and meta-analysis. Drug Saf 2021; 44:929–938.
Kucharz EJ, Szántó S, Ivanova Goycheva M, et al. Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. Rheumatol Int 2019; 39:1117–1123.
Bassetti M, Giacobbe DR, Bruzzi P, et al. Italian Society of Antiinfective Therapy and the Italian Society of Pulmonology (SIP) Clinical management of adult patients with COVID-19 outside intensive care units: guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther 2021; 10:1837–1885.
Veys EM. 20 years’ experience with ketoprofen. Scand J Rheumatol Suppl 1991; 90:1–44.
Varrassi G, Alon E, Bagnasco M, et al. Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus. Adv Ther 2019; 36:2618–2637.
Cimini A, Brandolini L, Gentile R, et al. Gastroprotective effects of L-lysine salification of ketoprofen in ethanol-injured gastric mucosa. J Cell Physiol 2015; 230:813–820.
Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six nonsteroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008; 101:1060–1063.
Saxena A, Balaramnavar VM, Hohlfeld T, Saxena AK. Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 2013; 721:215–224.
Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by nonsteroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109:825–833.